Yaolin Wang

发表

Analyses of p53 Target Genes in the Human Genome by Bioinformatic and Microarray Approaches* 210

Yaolin Wang, Luquan Wang, Luquan Wang, 2001, The Journal of Biological Chemistry.

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

E. Lees, T. Fischmann, P. Kirschmeier, 2010, Molecular Cancer Therapeutics.

linical Development aciclib ( SCH 727965 ) , a Novel and Potent Ther lin-Dependent Kinase Inhibitor

Parry, E. Lees, P. Kirschmeier, 2010 .

Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells

Yaolin Wang, Y. Lei, R. Miksicek, 2004, Breast Cancer Research and Treatment.

Procédés de traitement ou de prévention de cancer colorectal

W. R. Bishop, Yaolin Wang, Yan Wang, 2009 .

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.

E. Lees, T. Fischmann, P. Kirschmeier, 2010, ACS medicinal chemistry letters.

Impaired hepatocyte survival and liver regeneration in Atm-deficient mice.

Y. A. Wang, Yaolin Wang, S. Brooks, 2005, Human molecular genetics.

Regulable Expression of Inhibin A in Wild-Type and Inhibinα Null Mice

B. O’Malley, T. Pierson, M. Matzuk, 2000 .

Retinoic acid signaling is required for proper morphogenesis of mammary gland

Y. A. Wang, Yaolin Wang, S. Brooks, 2005, Developmental dynamics : an official publication of the American Association of Anatomists.

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.

Brian McKittrick, Yaolin Wang, Emma Lees, 2007, Bioorganic & medicinal chemistry letters.

Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction.

Yaolin Wang, J. Gesell, Yaolin Wang, 2004, Analytical biochemistry.

ATM and p21 cooperate to suppress aneuploidy and subsequent tumor development.

H. Heng, C. Deng, Yaolin Wang, 2005, Cancer research.

Ligand-inducible and liver-specific target gene expression in transgenic mice

Yaolin Wang, B. O’Malley, S. Tsai, 1997, Nature Biotechnology.

Pharmacogenomics of the p53 tumor suppressor and its role in cancer chemoresistance

W. R. Bishop, B. Dasmahapatra, Yaolin Wang, 2004 .

DNA methyltransferase-3a interacts with p53 and represses p53-mediated gene expression

Yaolin Wang, M. Hahn, Zhongliang Jiang, 2005, Cancer biology & therapy.

Induction of murine leukemia and lymphoma by dominant negative retinoic acid receptor α

Yaolin Wang, A. Kakizuka, Y. Ishida, 2005, Molecular carcinogenesis.

Phe19 Modification of HDM2-p53 PPI Inhibitors to Alleviate CYP3A4 Metabolism/Mechanism-based Inhibition Liability.

Yaolin Wang, T. Guzi, R. Doll, 2022, Bioorganic & medicinal chemistry letters.

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

H. Hirsch, M. Ayers, A. Loboda, 2014, PloS one.

A Novel Gene Regulatory System

M. Burcin, S. Tsai, Yaolin Wang, 1999 .

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody

W. R. Bishop, L. Presta, Yaolin Wang, 2005, Molecular Cancer Therapeutics.

Atm-haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors.

Yaolin Wang, Jie Chen, S. Brooks, 2006, Carcinogenesis.

ATM is activated by mitotic stress and suppresses centrosome amplification in primary but not in tumor cells

Yaolin Wang, A. Raz, S. Brooks, 2006, Journal of cellular biochemistry.

Characterization of estrogen receptor cDNAs from human uterus: identification of a novel PvuII polymorphism

Yaolin Wang, R. Miksicek, 1994, Molecular and Cellular Endocrinology.

Abstract PS11-26: A phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer

D. Juric, Bing-he Xu, Yaolin Wang, 2021 .

Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.

Yaolin Wang, R. Doll, B. Lahue, 2014, Bioorganic & medicinal chemistry letters.

Could microRNA be used as a diagnostic tool for lung cancer?

Yaolin Wang, Jian Guan, Yang Wang, 2019, Journal of cellular biochemistry.

A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts

W. R. Bishop, Yaolin Wang, Xiaoying Wang, 2010, Molecular Cancer Therapeutics.

Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.

W. R. Bishop, D. Hicklin, G. Scapin, 2016, ACS medicinal chemistry letters.

Abstract 5776: Pharmacologic and PK/PD study of D-0502: An orally bioavailable SERD with potent antitumor activity in ER-positive breast cancer cell lines and xenograft models

Yaolin Wang, Zhe Shi, Xing Dai, 2018, Experimental and Molecular Therapeutics.

In vitro and in vivo characterization of SCH727965 a novel potent cyclin dependent kinase inhibitor

E. Lees, P. Kirschmeier, Yaolin Wang, 2007 .

Identification of a dominant negative form of the human estrogen receptor.

Y. Wang, Yaolin Wang, R. Miksicek, 1991, Molecular endocrinology.

Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator

Y. Wang, J. Xu, T. Pierson, 1997, Gene Therapy.

SCH 727965, a novel cyclin-dependent kinase inhibitor, has potent anti-tumor acitivity in a wide-spectrum of human tumor xenograft models

Lingling Wu, D. Hicklin, E. Lees, 2008 .

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody

L. Presta, Yaolin Wang, Yan Wang, 2005, Molecular Cancer Therapeutics.